Adjuvant therapy for melanoma: how to choose?
Menée à partir de données portant sur 870 patients atteints d'un mélanome de stade III avec mutation V600 du gène BRAF et inclus dans un essai de phase III évaluant le dabrafénib en combinaison avec le tramétinib, cette étude analyse la performance de signatures, basées sur l'expression de l'interféron gamma et/ou la charge mutationnelle de la tumeur, pour identifier les patients pouvant bénéficier d'une thérapie ciblée
Compared with just 5 years ago, adjuvant therapy for stage III melanoma has undergone a major transformation. Immune checkpoint blockade and targeted therapies already approved in the metastatic stage IV melanoma setting have now been approved in the earlier adjuvant setting, providing long-awaited effective treatment options for patients for whom interferon-alfa 2b was the mainstay of approved therapy since its approval in 1995. 7
The decision about whether to prescribe a specific adjuvant therapy entails careful selection of patients on the basis of risk of disease relapse and likelihood of therapeutic efficacy, because, unlike in the metastatic setting, clinical response cannot be readily assessed, owing to the absence of measurable disease.
The Lancet Oncology , commentaire, 2019